MNKD vs. IRWD, LGND, OPK, DVAX, PAHC, ANAB, RDUS, LXRX, XOMA, and VNDA
Should you be buying MannKind stock or one of its competitors? The main competitors of MannKind include Ironwood Pharmaceuticals (IRWD), Ligand Pharmaceuticals (LGND), OPKO Health (OPK), Dynavax Technologies (DVAX), Phibro Animal Health (PAHC), AnaptysBio (ANAB), Radius Recycling (RDUS), Lexicon Pharmaceuticals (LXRX), XOMA (XOMA), and Vanda Pharmaceuticals (VNDA).
MannKind (NASDAQ:MNKD) and Ironwood Pharmaceuticals (NASDAQ:IRWD) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their community ranking, analyst recommendations, dividends, institutional ownership, profitability, risk, media sentiment, valuation and earnings.
MannKind currently has a consensus target price of $8.00, indicating a potential upside of 84.33%. Ironwood Pharmaceuticals has a consensus target price of $19.80, indicating a potential upside of 140.88%. Given Ironwood Pharmaceuticals' higher possible upside, analysts plainly believe Ironwood Pharmaceuticals is more favorable than MannKind.
MannKind has a beta of 1.28, indicating that its share price is 28% more volatile than the S&P 500. Comparatively, Ironwood Pharmaceuticals has a beta of 0.55, indicating that its share price is 45% less volatile than the S&P 500.
MannKind has a net margin of -6.00% compared to Ironwood Pharmaceuticals' net margin of -226.37%. MannKind's return on equity of 0.00% beat Ironwood Pharmaceuticals' return on equity.
MannKind has higher earnings, but lower revenue than Ironwood Pharmaceuticals. MannKind is trading at a lower price-to-earnings ratio than Ironwood Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
49.6% of MannKind shares are owned by institutional investors. 3.0% of MannKind shares are owned by company insiders. Comparatively, 13.1% of Ironwood Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
MannKind received 69 more outperform votes than Ironwood Pharmaceuticals when rated by MarketBeat users. However, 61.04% of users gave Ironwood Pharmaceuticals an outperform vote while only 59.83% of users gave MannKind an outperform vote.
In the previous week, MannKind had 1 more articles in the media than Ironwood Pharmaceuticals. MarketBeat recorded 6 mentions for MannKind and 5 mentions for Ironwood Pharmaceuticals. Ironwood Pharmaceuticals' average media sentiment score of 0.11 beat MannKind's score of 0.00 indicating that Ironwood Pharmaceuticals is being referred to more favorably in the news media.
Summary
MannKind beats Ironwood Pharmaceuticals on 9 of the 17 factors compared between the two stocks.
Get MannKind News Delivered to You Automatically
Sign up to receive the latest news and ratings for MNKD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MNKD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
MannKind Competitors List
Related Companies and Tools
